Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer-Reference-Cited by-同舟云学术

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Published:2019-04 Issue:3 Volume:27 Page:806-819.e5
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Choi Hyejin,Deng Jiehui,Li Shuai,Silk Tarik,Dong Lauren,Brea Elliott J.,Houghton Sean,Redmond David,Zhong Hong,Boiarsky Jonathan,Akbay Esra A.,Smith Paul D.,Merghoub Taha,Wong Kwok-Kin,Wolchok Jedd D.

Funder

Stand Up To Cancer-American Cancer Society Lung Cancer Dream Team Translational Research Grant

NIH-NCI Cancer Center

Ludwig Collaborative and Swim Across America Laboratory

Memorial Sloan Kettering Cancer Center

Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center

Department of Medicine, Memorial Sloan Kettering Cancer Center

Weill Cornell Medicine

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference58 articles.

1. PGC-1α promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs;Andrzejewski;Cell Metab.,2017

2. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias;Bolstad;Bioinformatics,2003

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

5. Clinically viable gene expression assays with potential for predicting benefit from MEK inhibitors;Brant;Clin. Cancer Res.,2017

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-04-24

3. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation;Molecular Cancer;2024-04-20

4. Targeting MEK in non-small cell lung cancer;Current Problems in Cancer;2024-04

5. Targeting metabolism to improve CAR-T cells therapeutic efficacy;Chinese Medical Journal;2024-03-19